Abstract
As has been emphasized in earlier chapters, the most dreaded complication of giant cell arteritis (GCA) is permanent visual loss in one or both eyes – and fear of visual loss is exceeded only by fear of death. If GCA is diagnosed early and treated immediately, aggressively and adequately with systemic corticosteroids, blindness is entirely preventable; that makes GCA the prime ophthalmic emergency. A study [1] further emphasized that fact, when it found that a high proportion of patients with permanent visual loss had had a delayed diagnosis and treatment; in that study 35% had experienced systemic symptoms for an average of 10.8 months before visual loss and 65% had had premonitory visual symptoms for an average of 8.5 days. This obviously raises two critical issues about the management of GCA: (1) how to establish an early and a definite diagnosis of GCA? and (2) what is the proper treatment to prevent blindness? There is a voluminous literature on both these topics; however, there is still a good deal of controversy on both issues [2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Font C, Cid MC, Coll-Vinent B, Lopez-Soto A, Grau JM. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol. 1997;36(2):251–4.
Hazelman BL, Bengtsson B-A. Giant cell arteritis and polymyalgia rheumatica. Baillières Clin Rheumatol. 1991;5:371–507 (see below).
Hayreh SS. Anterior ischaemic optic neuropathy. I. Terminology and pathogenesis. Br J Ophthalmol. 1974;58(12):955–63.
Hayreh SS. Anterior ischaemic optic neuropathy. II. Fundus on ophthalmoscopy and fluorescein angiography. Br J Ophthalmol. 1974;58(12):964–80.
Hayreh SS. Pathogenesis of cupping of the optic disc. Br J Ophthalmol. 1974;58(10):863–76.
Hayreh SS. Anterior ischemic optic neuropathy. New York: Springer; 1975.
Hayreh SS. Anterior ischemic optic neuropathy. Arch Neurol. 1981;38(11):675–8.
Hayreh SS. Posterior ischemic optic neuropathy. Ophthalmologica. 1981;182(1):29–41.
Hayreh SS. Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management. Eye. 1990;4(1):25–41.
Hayreh SS. Ophthalmic features of giant cell arteritis. Baillières Clin Rheumatol. 1991;5(3):431–59.
Hayreh SS. Acute ischemic disorders of the optic nerve: pathogenesis, clinical manifestations, and management. Ophthalmol Clin North Am. 1996;9(3):407–42.
Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123(3):285–96.
Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125(4):509–20.
Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;125(4):521–6. 893.
Hayreh SS. Masticatory muscle pain: an important indicator of giant cell arteritis. Spec Care Dentist. 1998;18(2):60–5.
Hayreh SS. Ocular manifestations of giant cell arteritis. Correspondence. Am J Ophthalmol. 1998;126(5):743–4.
Hayreh SS. Steroid therapy for visual loss in patients with giant-cell arteritis [erratum 2001;356(9227):434]. Lancet. 2000;355(9215):1572–3.
Hayreh SS, Jonas JB. Optic disk and retinal nerve fiber layer damage after transient central retinal artery occlusion: an experimental study in rhesus monkeys. Am J Ophthalmol. 2000;129(6):786–95.
Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand. 2002;80(4):355–67.
Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003;110(6):1204–15.
Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003;217(4):239–59.
Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347(4):261–71.
Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234–45.
Weyand CM, Goronzy JJ. Pathogenic principles in giant cell arteritis. Int J Cardiol. 2000;75 Suppl 1:S9–15. S15–S19.
Cornblath WT, Eggenberger ER. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology. 1997;104(5):854–8.
Chan CC, Paine M, O’Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85(9):1061–4.
Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27(6):1484–91.
Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310–8.
Kyle V. Treatment of polymyalgia rheumatica/giant cell arteritis. Baillières Clin Rheumatol. 1991;5(3):485–91.
Wilke WS, Hoffman GS. Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am. 1995;21(1):59–71.
Myles AB, Perera T, Ridley MG. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol. 1992;31(2):103–5.
Gouet D, Marechaud R, Le Berre D, Alcalay M, Becq-Giraudon B, Boissonnot L, et al. Pronostic de l’arterite temporale traitee. Etude retrospective de 87 observations. [Prognosis of treated temporal arteritis. Retrospective study of 87 cases]. Presse Méd. 1986;15(13):603–6.
Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703–8.
Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med. 1975;82(5):613–8.
Bengtsson BA, Malmvall BE. An alternate-day corticosteroid regimen in maintenance therapy of giant cell arteritis. Acta Med Scand. 1981;209(5):347–50.
Fauchald P, Rygvold O, Oystese B. Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings. Ann Intern Med. 1972;77(6):845–52.
Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978;88(2):162–7.
Kyle V, Hazelman BL. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. BMJ. 1990;300(6721):344–5.
Cullen JF. Temporal arteritis. Occurrence of ocular complications 7 years after diagnosis. Br J Ophthalmol. 1972;56(8):584–8.
Cohen DN. Temporal arteritis: improvement in visual prognosis and management with repeat biopsies. Trans Am Acad Ophthalmol Otolaryngol. 1973;77(1):OP74–85.
Blumberg S, Giansiracusa DF, Docken WP, Kantrowitz FG. Recurrence of temporal arteritis. Clinical recurrence nine years after initial illness. JAMA. 1980;244(15):1713–4.
Graham E, Holland A, Avery A, Russell RW. Prognosis in giant-cell arteritis. Br Med J (Clin Res Ed). 1981;282(6260):269–71.
Andersson R, Malmvall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand. 1986;220(5):465–9.
Salvarani C, Macchioni PL, Tartoni PL, Rossi F, Baricchi R, Castri C, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol. 1987;5(3):205–15.
Fernandez-Herlihy L. Duration of corticosteroid therapy in giant cell arteritis. J Rheumatol. 1980;7(3):361–4.
Beevers DG, Harpur JE, Turk KA. Giant cell arteritis: the need for prolonged treatment. J Chronic Dis. 1973;26(9):571–84.
Bengtsson BA, Malmvall BE. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand. 1981;209(5):337–45.
Graham E. Survival in temporal arteritis. Trans Ophthalmol Soc UK. 1980;100(Pt 1):108–10.
Arashvand K, Alexander WL, Dasgupta B. Duration of treatment after eye involvement in giant cell arteritis. J Rheumatol. 2007;34(9):1945.
Bengtsson BA, Malmvall BE. Giant cell arteritis. Acta Med Scand Suppl. 1982;658:65–72.
Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43(5):1041–8.
Hachulla E, Boivin V, Pasturel-Michon U, Fauchais AL, Bouroz-Joly J, Perez-Cousin M, et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol. 2001;19(2):171–6.
Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, Filella X, Esteban MJ, Lopez-Soto A, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 2002;47(1):29–35.
Ghanchi FD, Dutton GN. Current concepts in giant cell (temporal) arteritis. Surv Ophthalmol. 1997;42(2):99–123.
Whitfield AG, Cooke WT, Jameson-Evans P, Rudd C. Temporal arteritis and its treatment with cortisone and A.C.T.H. Lancet. 1953;1(6757):408–12.
Bennett G. Cortisone therapy of visual loss in temporal arteritis. Br J Ophthalmol. 1956;40(7):430–3.
Russell RWR. Giant cell arteritis. Q J Med. 1959;28(112):471–89.
Parsons-Smith G. Sudden blindness in cranial arteritis. Br J Ophthalmol. 1959;43(4):204–16.
Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100(4):550–5.
Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology. 1994;101(11):1779–85.
González-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41(8):1497–504.
Kupersmith MJ, Langer R, Mitnick H, Spiera R, Spiera H, Richmond M, et al. Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy. Br J Ophthalmol. 1999;83(7):796–801.
Foroozan R, Deramo VA, Buono LM, Jayamanne DG, Sergott RC, Danesh-Meyer H, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003;110(3):539–42.
Rosenfeld SI, Kosmorsky GS, Klingele TG, Burde RM, Cohn EM. Treatment of temporal arteritis with ocular involvement. Am J Med. 1986;80(1):143–5.
Postel EA, Pollock SC. Recovery of vision in a 47-year-old man with fulminant giant cell arteritis. J Clin Neuroophthalmol. 1993;13(4):262–70.
Matzkin DC, Slamovits TL, Sachs R, Burde RM. Visual recovery in two patients after intravenous methylprednisolone treatment of central retinal artery occlusion secondary to giant-cell arteritis. Ophthalmology. 1992;99(1):68–71.
Hayreh SS, Podhajsky PA, Zimmerman MB. Branch retinal artery occlusion: Natural history of visual outcome. Ophthalmology. 2009;116(6):1188–94.
Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. Am J Ophthalmol. 2005;140(3):376–91.
Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005;112(6):1098–103.
Grogan PM, Gronseth GS. Practice parameter: Steroids, acyclovir, and surgery for Bell’s palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(7):830–6.
Sharma S. Levels of evidence. Evid Based Eye Care. 2001;2(3):131–2.
Spencer WH, Hoyt WF. A fatal case of giant cell arteritis (temporal or cranial arteritis) with ocular involvement. AMA Arch Ophthalmol. 1960;64:862–7.
MacFaul PA. Ciliary artery involvement in giant cell arteritis. Br J Ophthalmol. 1967;51(8):505–12.
Henkind P, Charles NC, Pearson J. Histopathology of ischemic optic neuropathy. Am J Ophthalmol. 1970;69(1):78–90.
MacMichael IM, Cullen JF. Pathology of ischaemic optic neuropathy. In: Cant JS, editor. The optic nerve: proceedings of the second William Mackenzie Memorial Symposium held in Glasgow, 7–10 September 1971. London: Henry Kimpton Publishers; 1972. p. 108–16.
Hinzpeter EN, Naumann G. Ischemic papilledema in giant-cell arteritis. Mucopolysaccharide deposition with normal intraocular pressure. Arch Ophthalmol. 1976;94(4):624–8.
Hayreh SS. The ophthalmic artery: III. Branches. Br J Ophthalmol. 1962;46(4):212–47.
Hayreh SS. The 1994 Von Sallman lecture: The optic nerve head circulation in health and disease. Exp Eye Res. 1995;61(3):259–72.
Hayreh SS. The blood supply of the optic nerve head and the evaluation of it: myth and reality. Prog Retin Eye Res. 2001;20(5):563–93.
Hayreh SS, Baines JA. Occlusion of the posterior ciliary artery. I. Effects on choroidal circulation. Br J Ophthalmol. 1972;56(10):719–35.
Hayreh SS, Chopdar A. Occlusion of the posterior ciliary artery. V. Protective influence of simultaneous vortex vein occlusion. Arch Ophthalmol. 1982;100(9):1481–91.
Petrig BL, Riva CE, Hayreh SS. Laser Doppler flowmetry and optic nerve head blood flow. Am J Ophthalmol. 1999;127(4):413–25.
Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117(5):603–24.
Hayreh SS, Podhajsky PA, Zimmerman B. Nonarteritic anterior ischemic optic neuropathy: time of onset of visual loss. Am J Ophthalmol. 1997;124(5):641–7.
Hayreh SS, Podhajsky P, Zimmerman MB. Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica. 1999;213(2):76–96.
Hayreh SS, Zimmerman MB, Kimura A, Sanon A. Central retinal artery occlusion. Retinal survival time. Exp Eye Res. 2004;78(3):723–36.
Kearns TP. Discussion: temporal arteritis: Improvement in visual prognosis and management with repeat biopsies. Trans Am Acad Ophthalmol Otolaryngol. 1973;77(1):OP84–5.
Thystrup J, Knudsen GM, Mogensen AM, Fledelius HC. Atypical visual loss in giant cell arteritis. Acta Ophthalmol (Copenh). 1994;72(6):759–64.
Clearkin L, Caballero J. Recovery of visual function in anterior ischemic optic neuropathy due to giant cell arteritis. Am J Med. 1992;92(6):703–4.
Clearkin LG. IV steroids for central retinal artery occlusion in giant-cell arteritis. Ophthalmology. 1992;99(10):1482–4.
Richard G, Lerche RC, Knospe V, Zeumer H. Treatment of retinal arterial occlusion with local fibrinolysis using recombinant tissue plasminogen activator. Ophthalmology. 1999;106(4):768–73.
Hayreh SS. Retinal arterial occlusion with LIF using rTPA (Correspondence). Ophthalmology. 1999;106(7):1236–9. 2044.
Meadows SP. Temporal arteritis and the loss of vision. Trans Ophthalmol Soc UK. 1954;74:13–24.
Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy. J Am Med Assoc. 1957;163(10):821–7.
Mosher HA. The prognosis in temporal arteritis. AMA Arch Ophthalmol. 1959;62:641–4.
Whitfield AG, Bateman M, Cooke WT. Temporal arteritis. Br J Ophthalmol. 1963;47:555–66.
Meadows SP. Temporal or giant cell arteritis: ophthalmic aspects. In: Smith JL, editor. Neuro-ophthalmology: symposium of the University of Miami and the Bascom Palmer Eye Institute, vol. 4. St. Louis: Mosby; 1968. p. 148–57.
Smith JL. Editor’s note regarding Meadows SP. Temporal or giant cell arteritis: ophthalmic aspects. In: Smith JL, editor. Neuro-ophthalmology: Symposium of the University of Miami and the Bascom Palmer Eye Institute. St. Louis: Mosby; 1968: 4. p. 156.
Boghen DR, Glaser JS. Ischaemic optic neuropathy. The clinical profile and history. Brain. 1975;98(4):689–708.
Healey LA, Wilske KR. Manifestations of giant cell arteritis. Med Clin North Am. 1977;61(2):261–70.
Sørensen S, Lorenzen I. Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients. Acta Med Scand. 1977;201(3):207–13.
Hugod C, Scheibel M. Temporal arteritis–progressive affection of vision during high-level corticosteroid therapy. A case report. Acta Med Scand. 1979;205(5):445–6.
Calamia KT, Hunder GG. Clinical manifestations of giant-cell (temporal) arteritis. Clin Exp Rheumatol. 1980;6(2):389–403.
Herrick PC. Cranial arteritis. A preventable cause of blindness. Trans Ophthalmol Soc N Z. 1980;32:106–9.
Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis. 1981;40(1):1–5.
Bengtsson BA, Malmvall BE. Eye complications in giant cell arteritis. Acta Med Scand Suppl. 1982;658:38–43.
Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis. 1988;47(9):733–9.
Slavin ML, Margolis AJ. Progressive anterior ischemic optic neuropathy due to giant cell arteritis despite high-dose intravenous corticosteroids. Arch Ophthalmol. 1988;106(9):1167.
Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989;48(8):658–61.
Faarvang KL, Pontoppidan Thyssen E. Giant cell arteritis: loss of vision during corticosteroid therapy. J Intern Med. 1989;225(3):215–6.
Weinberg DA, Savino PJ, Sergott RC, Bosley TM. Giant cell arteritis. Corticosteroids, temporal artery biopsy, and blindness. Arch Fam Med. 1994;3(7):623–7.
Hwang JM, Girkin CA, Perry JD, Lai JC, Miller NR, Hellmann DB. Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite corticosteroid treatment. Am J Ophthalmol. 1999;127(1):102–4.
Schmidt D, Vaith P, Hetzel A. Prevention of serious ophthalmic and cerebral complications in temporal arteritis? Clin Exp Rheumatol. 2000;18(4 Suppl 20):S61–3.
Loddenkemper T, Sharma P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry. 2007;78(11):1255–9.
Wagener HP, Hollenhorst RW. The ocular lesions of temporal arteritis. Am J Ophthalmol. 1958;45(5):617–30.
Hollenhorst RW, Brown JR, Wagener HP, Shick RM. Neurologic aspects of temporal arteritis. Neurology. 1960;10:490–8.
Raymond LA, Sacks JG, Choromokos E, Khodadad G. Short posterior ciliary artery insufficiency with hyperthermia (Uhthoff’s symptom). Am J Ophthalmol. 1980;90(5):619–23.
González-Gay MA, Garcia-Porrúa C, Llorca J, Hajeer AH, Brañas F, Dababneh A, et al. Visual manifestations of giant cell arteritis Trends and clinical spectrum in 161 patients. Medicine Baltimore. 2000;79(5):283–92.
Cooke WT, Cloake PCP, Govan ADT, Colbeck JC. Temporal arteritis: a generalized vascular disease. Q J Med. 1946;15(1):47–75.
Cardell BS, Hanley T. A fatal case of giant-cell or temporal arteritis. J Pathol Bacteriol. 1951;63(4):587–97.
Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis. 1989;48(8):662–6.
Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol. 1994;21(7):1283–6.
Bevis T, Ratnakaram R, Smith MF, Bhatti MT. Visual loss due to central serous chorioretinopathy during corticosteroid treatment for giant cell arteritis. Clin Experiment Ophthalmol. 2005;33(4):437–9.
Steichen O, Chauveheid MP, Lidove O, Doan S, Papo T. Baisse de l’acuite visuelle chez une patiente traitee par corticoides pour maladie de Horton: chorioretinopathie sereuse centrale iatrogene. [Iatrogenic central serous chorioretinopathy during glucocorticoid therapy for temporal arteritis]. Rev Méd Interne. 2006;27(9):702–5.
Lespessailles E, Poupon S, Adriambelosoa N, Pothuaud L, Siroux V, Bouillon S, et al. Glucocorticoid-induced osteoporosis: is the bone density decrease the only explanation? Joint Bone Spine. 2000;67(2):119–26.
Cacoub P, Chemlal K, Khalifa P, Wechsler B, De Gennes C, Belmatoug N, et al. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. J Rheumatol. 2001;28(11):2474–9.
Chevalet P, Barrier JH, Glémarec J, el Kouri D, Hamidou M, de Wazières B, et al. Maladie de Horton du sujet age de plus de 75 ans: particularites evolutives, complications de la corticotherapie. Etude comparative sur une serie de 164 patients. Vers une dose d’attaque reduite. [Horton’s disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose]. Rev Méd Interne. 2001;22(7):624–30.
Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339(5):292–9.
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44(7):1496–503.
van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996;55(4):218–23.
Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495–501.
Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309–18.
Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106–14.
Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–97.
De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45(2):136–8.
Schaufelberger C, Mollby H, Uddhammar A, Bratt J, Nordborg E. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol. 2006;35(4):327–9.
Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621–30.
Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67(5):625–30.
Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol. 2007;26(8):1353–5.
Nesher G, Sonnenblick M. Steroid-sparing medications in temporal arteritis: report of three cases and review of 174 reported patients. Clin Rheumatol. 1994;13(2):289–92.
Cantini F, Niccoli L, Nannini C, Bertoni M, Salvarani C. Diagnosis and treatment of giant cell arteritis. Drugs Aging. 2008;25(4):281–97.
Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. 2004;14(3):245–57.
Bengtsson BA, Malmvall BE. Hematological observations in giant cell arteritis. Acta Med Scand Suppl. 1982;658:44–7.
Gibb WR, Urry PA, Lees AJ. Giant cell arteritis with spinal cord infarction and basilar artery thrombosis. J Neurol Neurosurg Psychiatry. 1985;48(9):945–8.
De Keyser J, De Klippel N, Ebinger G. Thrombocytosis and ischaemic complications in giant cell arteritis. BMJ. 1991;303(6806):825.
Kaiser M, Weyand CM, Bjornsson J, Goronzy JJ. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum. 1998;41(4):623–33.
Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, Lopez-Soto A, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41(1):26–32.
González-Gay MA, García-Porrua C, Vázquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol. 1998;25(9):1750–5.
González-Alegre P, Ruiz-Lopez AD, Abarca-Costalago M, Gonzalez-Santos P. Increment of the platelet count in temporal arteritis: response to therapy and ischemic complications. Eur Neurol. 2001;45(1):43–5.
Liozon E, Herrmann F, Ly K, Robert PY, Loustaud V, Soria P, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001;111(3):211–7.
Harrell FE. The LOGIST procedure. SUGI supplemental library user’s guide, version 5. Cary: SAS Institute, Inc; 1986. p. 269–93.
Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979;300(20):1142–7.
Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med. 1978;88(1):7–11.
Malmvall BE, Bengtsson BA. Giant cell arteritis. Clinical features and involvement of different organs. Scand J Rheumatol. 1978;7(3):154–8.
Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum. 1981;24(11):1414–8.
Lincoff NS, Erlich PD, Brass LS. Thrombocytosis in temporal arteritis rising platelet counts: a red flag for giant cell arteritis. J Neuroophthalmol. 2000;20(2):67–72.
Hu Z, Yang Q, Zheng S, Tang J, Lu W, Xu N, et al. Temporal arteritis and fever: report of a case and a clinical reanalysis of 360 cases. Angiology. 2000;51(11):953–8.
Foroozan R, Danesh-Meyer H, Savino PJ, Gamble G, Mekari-Sabbagh ON, Sergott RC. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2002;109(7):1267–71.
Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332–7.
Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54(10):3306–9.
Singh S, Dass R. The central artery of the retina. I. Origin and course. Br J Ophthalmol. 1960;44:193–212.
Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29(3 Suppl 10):16–21.
Crow RW, Katz BJ, Warner JE, Alder SC, Zhang K, Schulman S, et al. Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci. 2009;64(3):365–9.
Graham E. Survival in temporal arteritis. Trans Ophthalmol Soc UK. 1980;100(Pt 1):108–10.
Uddhammar A, Eriksson AL, Nystrom L, Stenling R, Rantapää-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol. 2002;29(4):737–42.
Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology Oxford. 2001;40(11):1238–42.
Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48(12):3532–7.
Pipitone N, Boiardi L, Bajocchi G, Salvarani C. Long-term outcome of giant cell arteritis. Clin Exp Rheumatol. 2006;24(2 Suppl 41):S65–70.
González-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454–61.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hayreh, S.S. (2011). Management of Giant Cell Arteritis to Prevent Visual Loss. In: Ischemic Optic Neuropathies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-11852-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-11852-4_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-11849-4
Online ISBN: 978-3-642-11852-4
eBook Packages: MedicineMedicine (R0)